CBS 2019
CBSMD教育中心
English

急性冠脉综合征

科研文章

荐读文献

Clinical and Angiographic Features of Patients With Out-of-Hospital Cardiac Arrest and Acute Myocardial Infarction Prognostic Value of the Residual SYNTAX Score After Functionally Complete Revascularization in ACS The year in cardiovascular medicine 2020: acute coronary syndromes and intensive cardiac care Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial Imaging Coronary Anatomy and Reducing Myocardial Infarction Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the Coronavirus Disease 2019 (COVID-19) Pandemic: An ACC /SCAI Consensus Statement High-Sensitivity Troponin and The Application of Risk Stratification Thresholds in Patients with Suspected Acute Coronary Syndrome Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and Platelet Reactivity: Analysis From ADAPT-DES A randomised trial comparing two stent sizing strategies in coronary bifurcation treatment with bioresorbable vascular scaffolds - The Absorb Bifurcation Coronary (ABC) trial Coronary CT Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome

Original Research2021 Mar 9.

JOURNAL:Diabetes Obes Metab. Article Link

Red Cell Distribution Width in Patients with Diabetes and Myocardial Infarction: an analysis from the EXAMINE trial

JP Ferreira, Z Lamiral, G Bakris et al. Keywords: alogliptin; outcomes; red cell distribution width; T2DM

ABSTRACT

BACKGROUND - Red blood cell distribution width (RDW) is a measure of size variability in the red blood cell population (anisocytosis). Increased RDW may arise from any condition that affects erythropoiesis or the survival of erythrocytes. RDW has been associated with poor prognosis in patients with type 2 diabetes (T2D). Whether RDW is a risk marker for adverse cardiovascular outcomes or also a marker of noncardiovascular health concerns is of clinical importance.

 

AIMS - To determine the clinical correlates of increased RDW, its potential mechanistic association with multiple circulating biomarkers, and its prognostic value, in patients with (T2D) who had a recent acute coronary syndrome.

 

METHODS - We used timeupdated Cox models applied to patients enrolled in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.

 

RESULTS - A total of 5380 patients were included, the median age was 61 years and 32% were women. Patients with higher RDW were older, more frequently women, with longer duration of diabetes duration, and increased comorbidities. An RDW >16.1% (both baseline and timeupdated) was independently associated with the study primary composite outcome of nonfatal myocardial infarction, nonfatal stroke or cardiovascular death (timeupdated adjusted HR =1.36, 95%CI =1.161.61, p < 0.001), allcause death (timeupdated adjusted HR =2.01, 95%CI =1.602.53, p < 0.001), as well as mortality from nonCV causes (timeupdated adjusted HR =2.67, 95%CI =1.724.15, p < 0.001). RDW had a weaktomoderate correlation with hemoglobin and circulating markers that reflected inflammation, apoptosis, fibrosis and congestion. Alogliptin did not alter RDW values.

 

CONCLUSIONS - RDW is a marker of disease severity associated with a multitude of poor outcomes, including both cardiovascular and noncardiovascular death. RDW correlated modestly with inflammatory, proapoptotic, profibrotic, and congestion markers, and its levels were not affected by alogliptin during the course of the trial.

 

This article is protected by copyright. All rights reserved.